Drugs / ALN-2232
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07463846 | Mar 2026 → Apr 2027 expected | obesity disorder | Alnylam Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALN-2232 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07463846 ↗ |
| Route | Subcutaneous | “ALN-2232 will be administered subcutaneously (SC)” NCT07463846 ↗ |